BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Prostate cancer relies on genetic "switches," called enhancers, that can turn on tumor-promoting genes. Researchers at the ...

Prostate cancer relies on genetic "switches", called enhancers, that can turn on tumor-promoting genes.

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

So, Citi Foundation identified youth employability as the theme for its $25 million Global Innovation Challenge this year.

Officials have identified more than 1,000 available hotel rooms plus additional rental options in Alaska’s largest city for ...